George Abraham, MD, offers insight into where the United States currently stands with regard to the COVID-19 pandemic, vaccine development, barriers to care in various patient populations, and the evolving roles of infectious disease specialists.
The investigational treatment from Regeneron consists of 2 potent, virus-neutralizing antibodies.
Pfizer and BioNTech will submit an Emergency Use Authorization (EUA) request to the FDA for their mRNA-based vaccine candidate BNT162b2 against COVID-19.
The analysis of the primary outcomes was based on 170 confirmed cases of COVID-19.
The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.
REGN-COV2 consists of 2 virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein.
Study authors measured seroprevalence of measles and mumps among cancer patients and compared seroprevalence based on demographic, disease, and treatment subgroups.
Bamlanivimab is a potent neutralizing IgG1 monoclonal antibody directed against the spike protein of severe acute respiratory syndrome coronavirus 2.
In the event of a likely scarcity of COVID-19 vaccines, a framework must be developed to inform who should get priority.
Study authors assessed the relationship between quadrivalent HPV vaccination and risk of invasive cervical cancer and age of vaccination.
